Optimization of prostate cancer diagnostics

Radiological Society of North America Trainee Research Prize for Jonathan Miksch, resident in the Department of Nuclear Medicine.

Jonathan Miksch, a resident in the Department of Nuclear Medicine, is recognized at this year's RSNA (Radiological Society of North America) annual meeting for his submitted paper:
"[F-18]siPSMA-14 PET/CT Acquired at 90 Minutes p.i. Without Forced Diuresis Provides Optimal Contrast for Staging and Restaging of Prostate Cancer Patients"  has been awarded the Trainee Research Prize. The prize is endowed with prize money of 1,000 US dollars.

In recent years, the use of radioactive substances with a target structure PSMA (prostate specific membrane antigen) has become established in nuclear imaging of prostate carcinoma. The work of Mr. Miksch presents the promising results of a new radioactive substance and its first clinical application in prostate cancer patients. F-18]siPSMA-14 is a comparatively easy tracer to produce in large quantities and showed optimal conditions for tumor detection 90 minutes after injection, both at initial diagnosis and in the recurrence situation.

The Radiological Society of North America is the world's largest association for radiologists, medical physicists and medical professionals.

Calculating the optimal tumor therapy

Award: Medical physicist Dr. Peter Kletting from Ulm receives the Science Award of the German Society for Medical Physics

The German Society for Medical Physics (DGMP) has awarded Dr. biol. hum. Peter Kletting, medical physicist at the Department of Nuclear Medicine at Ulm University Hospital, with the Science Award 2020 for his research on targeted irradiation of tumor tissue with radioactively labeled peptides.

You can read a detailed description of the research work here.
(Only in german language)

EMIM (ESMI) – Poster Award 2020

The Ulm research group for preclinical imaging, represented by Dr. Gordon Winter, was honored with the "Poster Award" for their contribution at the annual meeting (EMIM) of the European Society for Molecular Imaging (ESMI).

The award-winning work investigates the use of the chicken egg model as an alternative to animal testing with mice in the development of new radiolabeled substances. The results of the studies have already been published.

Nusrat Begum, PhD student in the Department of Nuclear Medicine, was honored with the 2019 Alavi Mandell Award.

Nusrat Jihan Begum, MSc, PhD student in the Department of Nuclear Medicine at Ulm University Hospital has been awarded the American Alavi-Mandell Prize for her publication in The Journal of Nuclear Medicine (JNM, impact factor 7.4 (2017)).

The prize was awarded for her publication entitled
( “The effect of total tumor volume on the biologically effective dose of tumor and kidneys for 177Lu-labelled PSMA peptides”).

Publication by Dr. Peter Kletting, Department of Nuclear Medicine at Ulm University Hospital, was awarded a prize by the German Society of Nuclear Medicine (DGN).

For his achievements in the field of nuclear medicine therapy, Dr. biol. hum. Peter Kletting, a member of staff at the Clinic for Nuclear Medicine | Medical Radiation Physics at Ulm University Hospital, has received this year's sponsorship award from the German Society for Nuclear Medicine (DGN). The award is endowed with 3,000 euros. The prize of the professional society is intended to honor scientific publications that make an outstanding contribution to the establishment or optimization of nuclear medicine therapies. For more information, please see the press release.
(Only in german language)

Dr. biol. hum. Peter Kletting (Ulm) has received one of the 3 Behnken-Berger Prizes 2017 for the development of a method to improve the therapeutic index for radioligand therapy. (Publication)

The award ceremony took place during the joint Annual Meeting of Biomedical Engineering and the Three-Country Meeting of Medical Physics in Dresden on September 11, 2017.

The awarded paper by Dr. Peter Kletting describes a method by the application of which the therapeutic index for radioligand therapy can be improved.

With the help of the physiologically based pharmacokinetic model developed by Dr. Kletting and the simulation algorithm, the combination of activity and amount of peptide used can be determined individually for each patient, leading to the optimal ratio of biologically effective dose in the tumor to organs at risk. As a result, the effectiveness of the therapy is increased while the radiation exposure remains the same, or the radiation exposure to the organs at risk can be minimized for a given effect. The developed method can be transferred to other substances and thus shows an extraordinary relevance for current and future therapy concepts. Therefore, they represent an important step in reducing the radiation exposure of patients. This outstanding work is closely related to the work published by Dr. Kletting so far in the field of therapeutic use with ionizing radiation.